Disappointing Worldwide Obesity Treatment Statistics: The hCG Method Deserves An Unbiased Review

Daniel Oscar Belluscio
The hCG Research Center- Buenos Aires, Argentina

Abstract:
The obesity epidemic is devastating the Social and Healthcare structure of developed and underdeveloped nations. In developed countries, obesity accounts for 1 out of 3 individuals. The medical care costs of obesity in the United States, for example, are high. In 2008 dollars, these costs were estimated to be $147 billion. The annual nationwide productive costs of obesity obesity-related absenteeism range between $3.38 billion ($79 per obese individual) and $6.38 billion ($132 per obese individual). Despite this thrilling data, obesity treatment results remain disappointing: gathered data is depressing, from surgical to non-surgical procedures. Short term weight loss does not result in long term weight loss.

The hCG method for obesity treatment: an overlooked alternative.

Despite their critics, the hCG (Human Chorionic Gonadotropin) + diet protocol survived for the past 65 years: clear evidence that the procedure outpassed the test of time.

About seventy years ago his author: Dr. ATW Simeons was the first Physician to suggest that the problem of obesity is not related to weight as registered on a bath scale, but in the increased amount of total body fat.

Biography:
Dr. Belluscio devoted most of his medical career to the study of hCG for weight loss. For several years he was a researcher at Bellevue Klinik, Switzerland, an institution with the most impressive records of treated patients with hCG (15,000) for obesity and overweight. He traveled to the U.S., Mexico, Sweden, Italy, Germany, and Israel, lecturing on the method. In 1987 he founded The Oral hCG Research Center, an institution devoted to the utility of hCG for obesity treatment. Records show that the center used the hCG Oral method in over 9,000 patients. Back in 1991, he developed an oral hCG formulation, which demonstrated its effectiveness in a series of Double-blind studies. Together with Dr. Vogt, Director of Bellevue Klinik, published several reports on the method aimed at Healthcare Professionals, and articles on the subject for the general public. OralhCG has been registered as a TM, with patents published and pending, both in Argentina and the United States. These patents and registrations include the brand: oralhCG, as well as various pharmaceutical sublingual formulations. These formulations have been used in his private practice for his patients for over 25 years. Currently, Dr. Belluscio participates in international medical congresses and gives lectures and lectures to the global medical community on the hCG Protocol and the formula he has developed.

Publication of speakers: